Options Predictions Based on Artificial Intelligence: Returns up to 351.34% in 3 Months

Options Predictions

This forecast is part of the Options Package, as one of I Know First’s algorithmic trading tools. The full Top 10 Options forecast includes daily predictions for the best options to buy for a total of 20 stocks with bullish and bearish signals:

  • Top 10 Call Options
  • Top 10 Put Options

Options
Package Name: Options
Recommended Positions: Long
Forecast Length: 3 Months (4/23/2020 – 7/23/2020)
I Know First Average: 69.23%
Options Predictions
Options Predictions chart

During the 3 Months forecasted period several picks in the Options Package saw significant returns. The algorithm had correctly predicted 9 out 10 returns. The top-performing prediction in this forecast was CLDX, which registered a return of 351.34%. QDEL and TWOU followed with returns of 107.94% and 103.1% for the 3 Months period. The Options package had an overall average return of 69.23%, providing investors with a premium of 53.64% over the S&P 500’s return of 15.59%.

Celldex Therapeutics, Inc., incorporated on December 9, 1983, is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. The Company is using the technologies to develop targeted immunotherapeutics consisting of protein-based molecules, such as vaccines, antibodies and antibody-drug conjugates that are used to treat specific types of cancer or other diseases. The Company’s lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is in clinical studies for the treatment of glioblastoma patients that express a specific cancer marker known as type III epidermal growth factor receptor mutation (EGFRvIII). Its Glembatumumab vedotin (also referred to as CDX-011) is a targeted antibody-drug conjugate for the treatment of metastatic melanoma. Its Varlilumab (also referred to as CDX-1127) is an immune modulating antibody that is designed to enhance a patient’s immune response against their cancer. The Company’s earlier stage drug candidates in clinical development include CDX-1401, which is a targeted immunotherapeutic aimed at antigen presenting cells (APC) for cancer indications and CDX-301, which is an immune cell mobilizing agent and dendritic cell growth factor. The Company’s pipeline also includes CDX-0158 and CDX-3379.

Algorithmic traders utilize these daily forecasts by the I Know First market prediction system as a tool to enhance portfolio performance, verify their own analysis and act on market opportunities faster. This forecast was sent to current I Know First subscribers.

How to interpret this diagram

Algorithmic Stock Forecast: The table on the left is a stock forecast produced by I Know First’s algorithm. Each day, subscribers receive forecasts for six different time horizons. Note that the top 10 stocks in the 1-month forecast may be different than those in the 1-year forecast. In the included table, only the relevant stocks have been included. The boxes are arranged according to their respective signal and predictability values (see below for detailed definitions). A green box represents a positive forecast, suggesting a long position, while a red represents a negative forecast, suggesting a short position.

Please note-for trading decisions use the most recent forecast. Get today’s forecast and Top stock picks.